LataMed AI Corp. (OTC: LMED), a healthcare technology company developing digital health and artificial intelligence solutions for Latin America, announced today that it will participate in the Artificial Intelligence & Health Markets 2026 conference, scheduled for August 13 and 14, 2026, at Universidad Santa Maria in Caracas, Venezuela. The event, organized through its Venezuelan operating subsidiary LATAMEDAI VE, aims to bring together students, faculty, and participants from systems engineering and healthcare-related academic communities to explore practical applications of AI and automation in medical and technical environments.
Representing LataMed AI will be Dr. Kevin Rodan Levy, Chief Executive Officer, and Carlos Pena, Chief Financial Officer. Their presentation will address the evolving role of artificial intelligence in healthcare, systems engineering, digital infrastructure, and professional decision-making. The company intends to discuss how AI-supported tools can assist healthcare professionals with medical-data evaluation, clinical workflows, and operational decision-making, as well as how automation may support the organization, reliability, and efficiency of technology systems in healthcare and other complex settings.
A key theme of the presentation will be the importance of maintaining qualified professional oversight when implementing AI. LataMed AI emphasizes that its technologies are designed to enhance human capabilities and support informed decision-making, not replace the independent judgment of healthcare professionals, engineers, laboratory personnel, or other qualified individuals. Additional conference topics will include integration of AI and automation into existing systems, responsible data use, privacy and information security, operational risk management, and practical considerations for developing and deploying technology in healthcare.
The company also plans to discuss the continued development of its healthcare technology ecosystem, particularly the roles of CardioAI, PulmoAI, and NeuroAI within its broader strategy. These AI-supported platforms are being developed to assist healthcare professionals in evaluating and managing cardiovascular, pulmonary, and neurological health information, subject to ongoing development, testing, regulatory requirements, and commercial implementation.
“Artificial Intelligence & Health Markets 2026 provides an important opportunity to engage directly with students, educators, and future professionals who will help shape the responsible use of artificial intelligence in healthcare and systems engineering,” said Dr. Kevin Rodan Levy. “Our objective is to share practical perspectives on how intelligent technologies can support professional decision-making, improve digital workflows, and contribute to the continued development of healthcare infrastructure in Latin America.”
Management believes that engagement with universities can increase awareness of emerging healthcare technologies, encourage responsible discussion about AI, and strengthen relationships with future professionals. The company also views this participation as a chance to better understand the perspectives of students, educators, researchers, and technical professionals as it continues developing digital health solutions for Latin America. The participation aligns with its broader strategy of supporting education, professional collaboration, and responsible adoption of digital healthcare infrastructure throughout the region.
For more information about LataMed AI and its initiatives, visit https://latamed.ai or review the company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
